在胰腺腺癌的辅助化疗和放射治疗
Sylvia S W Ng1, Sheron Perera2, Natalie G Coburn3
1Department of Radiation Oncology, Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada.
Surgical oncology clinics of North America
|November 13, 2025
概括
辅助化学辐射可能在手术和化疗后对选择的胰腺癌患者有益,可能降低局部复发风险. 多学科讨论是定制治疗的关键,在R1患者具有良好的表现状态.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 辐射瘤学 辐射瘤学
背景情况:
- 辅助化疗对切除的胰腺管道腺癌有益.
- 除了现代化疗方案之外,辅助化疗辐射的作用仍然存在争议,因为研究有限.
研究的目的:
- 评估辅助化学辐射在切除的胰腺管道腺癌中的作用.
- 为解决关于胰腺癌辅助环境中的化疗辐射的持续辩论.
主要方法:
- 文献综述和现有临床研究的综合.
- 对接受辅助化疗,有或没有化疗辐射的患者的结局结果的分析.
- 专注于当代治疗方案,如mFOLFIRINOX和gemcitabine/capecitabine,使用现代辐射技术.
主要成果:
- 已经确立了辅助化疗的临床益处.
- 很少有研究将现代化疗 (mFOLFIRINOX,gemcitabine/capecitabine) 与现代化疗辐射技术相结合.
- 对于具有良好表现状态的R1患者,可以考虑辅助化疗,以减少局部复发.
结论:
- 辅助化学辐射的决定应该是个性化的,并基于多学科团队的投入.
- 对选择R1胰腺癌患者进行化疗后考虑辅助化疗可能是适当的,以减轻局部复发.
- 需要进一步的临床研究来澄清化学辐射在辅助剂环境中的最佳作用.
更多相关视频
13:56Robot Assisted Distal Pancreatectomy with Celiac Axis Resection DP-CAR for Pancreatic Cancer: Surgical Planning and Technique
Published on: August 14, 2021
7.1K
08:12Laparoscopic Pancreatoduodenectomy for Pancreatic Cancer Using In-Situ No-Touch Isolation Technique
Published on: February 2, 2022
2.5K
相关概念视频
01:29Chronic Pancreatitis II: Collaborative Care
303
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
303
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
581
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
581
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
543
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
543